


Ask a doctor about a prescription for DOBUTAMINE HOSPIRA 12.5 mg/ml CONCENTRATE FOR INFUSION SOLUTION
Package Leaflet: Information for the User
Package Leaflet: Information for the User
DOBUTAMINE HOSPIRA 12.5 mg/ml
Concentrate for solution for infusion EFG
Dobutamine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack and other information:
Dobutamine belongs to a group of medicines that increase the heart's contraction force.
Dobutamine is used in patients who need a stronger heartbeat due to decreased heart function, which is caused by heart disease or surgery. By direct action on the heart, dobutamine gives the heart more contraction power.
Dobutamine may be used to detect poor blood supply to the heart (cardiac stress test).
Do not use Dobutamine Hospira 12.5 mg/ml
If you have certain blood vessel or heart disorders, dobutamine should not be used to detect poor blood supply to the heart.
Warnings and precautions
Be especially careful with Dobutamine Hospira 12.5 mg/ml
Children and adolescents
Special care should be taken when administering dobutamine to children under 1 year of age. They may react differently to adults.
Using Dobutamine Hospira 12.5 mg/ml with other medicines
Other medicines may be affected by dobutamine. They, in turn, may affect dobutamine. Dobutamine may interact with:
Tell your doctorif you are using or have recently used other medicines, even those bought without a prescription.
Using Dobutamine Hospira 12.5 mg/ml with food and drinks
Food and drink do not affect the effects of dobutamine.
Pregnancy and breastfeeding
If you are pregnant, you should not use dobutamine. There is not enough data to assess the potential harmful effects of dobutamine administration during pregnancy.
If you are breastfeeding, you should interrupt it during the duration of treatment with dobutamine.
Consult your doctor or pharmacist before taking any medicine.
Driving and using machines
There is no data on the influence of this product on the ability to drive and use machines. However, the effect is not predictable.
Important information about some of the ingredients of Dobutamine Hospira 12.5 mg/ml
Dobutamine contains sodium metabisulfite. Sulfites can rarely cause severe hypersensitivity reactions and bronchospasm.
As a general rule, this medicine will be administered by a doctor or healthcare professional.
The dose (infusion rate and treatment duration) may be different for each patient and will be determined by the doctor.
Dobutamine should be added to an infusion bag using a sterile syringe with a glucose or saline solution.
The action of dobutamine starts 1-2 minutes after administration.
During administration, the colorless solution may acquire a pink color without affecting the activity.
If you are given more Dobutamine 12.5 mg/ml than you should:
The following symptoms may indicate that you have received more dobutamine than you should:
The effect of dobutamine is only short-term. To alleviate the mentioned symptoms, it is sufficient to temporarily pause the administration of dobutamine or reduce the infusion rate until it stabilizes.
Consult your doctor or pharmacist if you have any questions about your treatment.
Like all medicines, dobutamine can have side effects, although not everybody gets them. If you experience any side effect, it is important that you inform your doctor before starting the next treatment.
The following side effects have been reported:
Very common (affects more than 1 in 10 patients)
Common (affects up to 1 in 10 patients)
Uncommon (affects up to 1 in 100 patients)
Rare (affects up to 1 in 1,000 patients)
Unknown frequency (cannot be estimated from the available data)
Reporting of side effects:
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children
Do not use this medicine after the expiry date which is stated on the carton after EXP. The first two digits indicate the month and the last four digits indicate the year. The expiry date refers to the last day of the month stated.
Before dilution
Store in the original package between 2 – 30°C. Do not freeze.
Diluted product
If the dilution is performed under strict aseptic conditions, the diluted product is stable for 24 hours at 15-25°C (room temperature).
If the dilution is not performed under strict aseptic conditions, the diluted product is stable for a maximum of 24 hours at 2-8°C (in the refrigerator), or 12 hours at 15-25°C (room temperature).
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Dobutamine Hospira 12.5 mg/ml
Appearance and packaging
Dobutamine is a clear and colorless concentrate for solution for infusion packaged in transparent glass ampoules with a colored spot.
The slightly pink color of the solution may intensify over time, without affecting the activity of the solution.
Dobutamine is available in packs of 1.5 or 10 ampoules of 20 ml.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
HOSPIRA INVICTA, S.A.
Avda. de Europa 20-B - Parque Empresarial La Moraleja
28108 Alcobendas, Madrid-Spain
Manufacturer
ANTIGEN PHARMACEUTICALS LTD.Roscrea (Roscrea, County Tipperary) - - - Ireland orSYNTHON HISPANIA, S.L.Castello 1, Poligono Las Salinas. (Sant Boi de Llobregat (Barcelona)) - 08830 – Spain
Local representative:
PFIZER S.L.
Avenida de Europa, 20 B – Parque Empresarial La Moraleja
28108,Alcobendas (Madrid)-Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Netherlands: Dobutamine 12.5 mg/ml concentrate for infusion
Belgium: Dobutamine EG 250 mg/20 ml concentrate for solution for intravenous infusion
Luxembourg: Dobutamine EG solution for infusion
Portugal: Dobutamine Genthon 12.5 mg/ml concentrate for solution for infusion
Date of last revision of this leaflet03/2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for DOBUTAMINE HOSPIRA 12.5 mg/ml CONCENTRATE FOR INFUSION SOLUTION – subject to medical assessment and local rules.